SCHEMBL1821209

SCHEMBL1821209

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)Nc1cccc(C(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 7/20 0.54
▸ NPC1 O15118 6/20 0.54
▸ RAB9A P51151 6/20 0.54
▸ HTT P42858 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ FAAH O00519 1/20 0.48
▸ MAPT P10636 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MITF O75030 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ PAX8 Q06710 1/20 0.47
▸ KLF5 Q13887 1/20 0.47
▸ NR1H4 Q96RI1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1821211 1.00 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9AHTTALDH1A1
SCHEMBL17614786 0.91 KMT2A (0.56) SMN1; SMN2NPC1RAB9AHTTALDH1A1
SCHEMBL16366081 0.89 KMT2A (0.63) ALDH1A1KMT2AMEN1L3MBTL1FAAH
SCHEMBL2678251 0.88 ALDH1A1 (0.59) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL2678248 0.88 ALDH1A1 (0.59) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL469507 0.82 SELP (0.55) ALDH1A1FAAHMAPTNR1H4
SCHEMBL10077432 0.82 SELP (0.55) ALDH1A1FAAHMAPTNR1H4
SCHEMBL454877 0.82 SELP (0.55) ALDH1A1FAAHMAPTNR1H4
SCHEMBL16366091 0.81 MEN1 (0.67) ALDH1A1KMT2AMEN1FAAHMAPT
SCHEMBL11221078 0.81 SMN1; SMN2 (0.64) SMN1; SMN2NPC1RAB9AHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210169905-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2021-06-10 — — US disclosed
US-20210169905-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2021-06-10 — — US disclosed
US-20200046738-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2020-02-13 — — US disclosed
US-20200046738-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2020-02-13 — — US disclosed
US-20180325923-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2018-11-15 — — US disclosed
EP-2813486-B1 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS INC (US) 2017-10-25 — — EP disclosed
EP-2315740-B1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS INC (US) 2017-10-25 — — EP disclosed
EP-2813486-B1 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS INC (US) 2017-10-25 — — EP disclosed
EP-2315740-B1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS INC (US) 2017-10-25 — — EP disclosed
US-20170246193-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2017-08-31 — — US disclosed
US-8173831-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2012-05-08 — — US disclosed
EP-2315740-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES Catabasis Pharmaceuticals, Inc. (US) 2011-05-04 — — EP disclosed
US-20100184730-A1 Fatty Acid Acylated Salicylates and Their Uses CATABASIS PHARMACEUTICALS, INC. 2010-07-22 — — US disclosed
US-20100184730-A1 Fatty Acid Acylated Salicylates and Their Uses CATABASIS PHARMACEUTICALS, INC. 2010-07-22 — — US disclosed
US-20100184730-A1 Fatty Acid Acylated Salicylates and Their Uses CATABASIS PHARMACEUTICALS, INC. 2010-07-22 — — US disclosed
US-20100041748-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2010-02-18 — — US disclosed
US-20100041748-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2010-02-18 — — US disclosed
US-20100041748-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2010-02-18 — — US disclosed
WO-2010006085-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2010-01-14 — — WO disclosed
WO-2010006085-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2010-01-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200046738-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 SMN1; SMN2 3528/4885NPC1 410/4885RAB9A 4462/4885
US-20180325923-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 SMN1; SMN2 3528/4885NPC1 410/4885RAB9A 4462/4885
US-20170246193-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 SMN1; SMN2 3528/4885NPC1 410/4885RAB9A 4462/4885
US-20100041748-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 SMN1; SMN2 3528/4885NPC1 410/4885RAB9A 4462/4885
US-20210169905-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 SMN1; SMN2 3528/4885NPC1 410/4885RAB9A 4462/4885
US-20100184730-A1 Fatty Acid Acylated Salicylates and Their Uses FADS1, FASN, ALOX5 SMN1; SMN2 2882/4885NPC1 654/4885RAB9A 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback